Rallybio Corp

Rallybio Corporation is a clinical-stage biotechnology company focused on developing and commercializing therapies for severe and rare diseases. Its lead candidate, RLYB116, is a complement component 5 (C5) inhibitor that has completed a phase 1 trial for diseases of complement dysregulation. The company also has a preclinical antibody, RLYB332, for severe anemia with ineffective erythropoiesis and iron overload. Rallybio has a strategic alliance with AbCellera and a collaboration with Johnson & Johnson, and was founded in 2018 in New Haven, Connecticut.